RA Capital Healthcare Fund LP
SEC CIK 1315082 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | Dir | 6,200 | — | — | 1 | 2026-02-19 | 2026-02-19 |
| EVMN | Evommune, Inc. | Dir | 2.71M | — | — | 1 | 2026-02-17 | 2026-02-17 |
| SGP | SpyGlass Pharma, Inc. | Dir, 10% | 5.97M | $59.04M | — | 2 | 2026-02-09 | 2026-02-09 |
| CLYM | Climb Bio, Inc. | Dir, 10% | 3.40M | $24.9K | — | 1 | 2026-01-05 | 2026-01-05 |
| FULC | Fulcrum Therapeutics, Inc. | 10% | 6.15M | $1.32M | $58.38M | 2 | 2023-01-04 | 2025-12-08 |
| PEPG | PepGen Inc. | Dir, 10% | 18.55M | $30.00M | — | 1 | 2025-09-26 | 2025-09-26 |
| WVE | Wave Life Sciences, Inc. | Dir, 10% | 28.8K | $20.38M | — | 2 | 2022-06-16 | 2025-08-11 |
| JANX | Janux Therapeutics, Inc. | Dir, 10% | 6,250 | $25.34M | — | 2 | 2025-03-05 | 2025-06-11 |
| TYRA | Tyra Biosciences, Inc. | Dir, 10% | 10.10M | $21.74M | — | 2 | 2024-11-08 | 2025-06-09 |
| ABOS | Acumen Pharmaceuticals, Inc. | Dir, 10% | 12.8K | — | — | 1 | 2025-06-04 | 2025-06-04 |
| ANTX | AN2 Therapeutics, Inc. | 10% | 1.73M | — | $3.81M | 1 | 2024-08-09 | 2024-08-09 |
| ACRV | Acrivon Therapeutics, Inc. | Dir, 10% | 7.91M | $42.37M | — | 3 | 2022-11-17 | 2024-04-11 |
| SPRY | ARS Pharmaceuticals, Inc. | Dir | 8.37M | $8.18M | — | 1 | 2023-09-21 | 2023-09-21 |
| CTKB | Cytek Biosciences, Inc. | Dir, 10% | 13.14M | $7.19M | — | 1 | 2022-03-14 | 2022-03-14 |
Most active insiders at MLYS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Catalys Pacific Fund, LP | 10% | — | $43.35M |
| 2 | Congleton Jon | CEO, Dir | — | $14.91M |
| 3 | Rodman David Malcom | Chief Medical Off | — | $14.41M |
| 4 | Shah Rajeev M. | Dir | $8.76M | — |
| 5 | Levy Adam Scott | CFO, Sec | — | $6.16M |
| 6 | Warren Eric | Chief Commercial Off | — | $3.30M |
| 7 | Gold Alexander M | Dir | — | $1.58M |
| 8 | Karydas Daphne | Dir | — | $925.6K |
| 9 | Slingsby Brian Taylor | Dir, 10% | — | — |
| 10 | DiRocco Derek | Dir | — | — |
| 12 | RA Capital Healthcare Fund LP | Dir | — | — |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-02-20 | 2026-02-19 | MLYS | Mineralys Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir | A - Grant | $0.00 | +6,200 | 6,200 | New | $0 |
| I | 2026-02-17 | 2026-02-17 | EVMN | Evommune, Inc. | RA Capital Healthcare Fund LP | Dir | A - Grant | $27.88 | +35.9K | 2.71M | +1% | +$1000.0K |
| DMI | 2026-02-11 | 2026-02-09 | SGP | SpyGlass Pharma, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $16.00 | +3.69M | 5.97M | +162% | +$59.04M |
| DMI | 2026-02-11 | 2026-02-09 | SGP | SpyGlass Pharma, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | C - Cnv Deriv | — | +4.33M | 2.52M | New | — |
| I | 2026-01-07 | 2026-01-05 | CLYM | Climb Bio, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $3.50 | +7,111 | 3.40M | +0.2% | +$24.9K |
| MI | 2025-12-10 | 2025-12-08 | FULC | Fulcrum Therapeutics, Inc. | RA Capital Healthcare Fund LP | 10% | S - Sale | $13.98 | -4.18M | 6.15M | -40% | -$58.38M |
| I | 2025-09-30 | 2025-09-26 | PEPG | PepGen Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $3.20 | +9.38M | 18.55M | +102% | +$30.00M |
| DI | 2025-08-13 | 2025-08-11 | WVE | Wave Life Sciences, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | A - Grant | $0.00 | +12.7K | 28.8K | +79% | $0 |
| DI | 2025-06-13 | 2025-06-11 | JANX | Janux Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | A - Grant | $0.00 | +3,750 | 6,250 | +150% | $0 |
| I | 2025-06-11 | 2025-06-09 | TYRA | Tyra Biosciences, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $10.19 | +186.8K | 10.10M | +2% | +$1.90M |
| DI | 2025-06-05 | 2025-06-04 | ABOS | Acumen Pharmaceuticals, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | A - Grant | $0.00 | +12.8K | 12.8K | New | $0 |
| MI | 2025-03-07 | 2025-03-05+ | JANX | Janux Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $30.75 | +824.0K | 9.66M | +9% | +$25.34M |
| I | 2024-11-13 | 2024-11-08 | TYRA | Tyra Biosciences, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $16.25 | +1.22M | 8.70M | +16% | +$19.84M |
| MI | 2024-08-13 | 2024-08-09 | ANTX | AN2 Therapeutics, Inc. | RA Capital Healthcare Fund LP | 10% | S - Sale | $1.08 | -3.53M | 1.73M | -67% | -$3.81M |
| I | 2024-04-15 | 2024-04-11 | ACRV | Acrivon Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | A - Grant | $8.50 | +3.53M | 7.91M | +81% | +$30.00M |
| MI | 2023-09-25 | 2023-09-21 | SPRY | ARS Pharmaceuticals, Inc. | RA Capital Healthcare Fund LP | Dir | P - Purchase | $3.03 | +2.70M | 8.37M | +48% | +$8.18M |
| MI | 2023-01-06 | 2023-01-04 | FULC | Fulcrum Therapeutics, Inc. | RA Capital Healthcare Fund LP | 10% | P - Purchase | $7.28 | +180.7K | 9.63M | +2% | +$1.32M |
| DMI | 2022-11-21 | 2022-11-17 | ACRV | Acrivon Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | C - Cnv Deriv | — | +1.42M | 994.7K | New | — |
| DI | 2022-11-21 | 2022-11-17 | ACRV | Acrivon Therapeutics, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $12.50 | +3.39M | 4.38M | +341% | +$42.37M |
| DI | 2022-06-21 | 2022-06-16 | WVE | Wave Life Sciences, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $2.15 | +9.48M | 17.20M | +123% | +$20.38M |
| MI | 2022-03-16 | 2022-03-14+ | CTKB | Cytek Biosciences, Inc. | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $12.32 | +583.9K | 13.14M | +5% | +$7.19M |
Purchase Sale Sale after option exercise All abbreviations